Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes

Patient-reported ECOG performance status (PS) is lower than oncologist-reported PS and is associated with worse psychosocial outcomes

kidneycancer

3 weeks
17 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Cristiane Decat Bergerot, PhD Psychologist, Postdoctoral Fellow City of Hope Comprehensive Cancer Center And colleagues Paulo Bergerot, MD; Errol Philip, PhD; JoAnn Hsu, BS; Nazli Dizman, MD; Meghan Salgia; Dena Battle; Ulka Vaishampayan, MD; Matthew Loscalzo, LCSW; William Dale, MD, PhD; Sumanta K. Pal, MD Filmed at the 18th International Kidney Cancer Symposium 2019, Miami, FL.

Up Next Autoplay
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Novartis Kisqali® data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Category: Breast Cancer
0 Views
cancernewsupdate 9 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL: How This Affects Clinicians? #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 32 minutes
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Venetoclax-Rituximab (VenR) in Relapsed Refractory (R/R) CLL #ASH19 #ASH
Category: Chronic Lymphocytic Leukemia
0 Views
ash 36 minutes
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Apixaban, LMWH, and Warfarin Among Venous Thromboembolism Patients #ASH19
Category: General
1 Views
ash 13 hours
Safety and Effectiveness of Apixaban #ASH19
Safety and Effectiveness of Apixaban #ASH19
Category: General
1 Views
ash 13 hours
Brentuximab Vedotin with Chemotherapy #ASH19
Brentuximab Vedotin with Chemotherapy #ASH19
Category: Chronic Myelogenous Leukemia
0 Views
ash 19 hours
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
4-Year Update of the Echelon-1 Study #ASH19 #ASH @TakedaOncology
Category: Chronic Lymphocytic Leukemia
4 Views
ash 21 hours
SWAY Study @LevineCancer #ASH19
SWAY Study @LevineCancer #ASH19
Category: Chronic Lymphocytic Leukemia
0 Views
ash 22 hours
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Sickle Cell Research: What's Next? #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Unmet Needs in Sickle Cell Research #ASH19 #ASH @LevineCancer
Category: Chronic Lymphocytic Leukemia
0 Views
ash 23 hours